研究单位：[1]Peking Union Medical College Hospital[2]Affiliated Hangzhou First People''s Hospital,Hangzhou,Zhejiang,China,310006[3]Xuanwu Hospital, Capital Medical University,Beijing,Beijing,China,100010[4]Nanfang Hospital, Southern Medical University,Guangzhou,Guangdong,China,510515[5]Affiliated Hospital of Zunyi Medical University,Zunyi,Guizhou,China,563003[6]First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China,150001[7]Third Xiangya Hospital of Central South University,Changsha,Hunan,China,410013[8]First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,China,210029[9]Affiliated Hospital of Yangzhou University,Yangzhou,Jiangsu,China,225000[10]First Affiliated Hospital of Dalian Medical University,Dalian,Liaoning,China,116011[11]First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shaanxi,China,710061[12]First Affiliated Hospital of Zhejiang University,Hangzhou,Zhejiang,China,310003
研究目的：
Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) is the second leading cause in China and is receiving increasing global attention. Research on HTG-AP has been hindered by the heterogeneity and complexity of the disease, as well as the limitations of prior single-center studies with small sample sizes, inadequate collection of clinical data, lack of sustainable follow-up, and insufficient tools for large-scale data collection, analysis, and biomarker testing. To address these unique challenges and leverage the opportunity to gain a deeper understanding of HTG-AP, the China Hypertriglyceridemia Pancreatitis Study Group (CHPSG) was initiated in April 2023 as a multi-center collaboration. By utilizing the advantages of multi-center studies, such as external validity and larger sample sizes, CHPSG aims to investigate the prevalence, clinical characteristics, natural history, and risk factors of HTG-AP in China. The consortium will also explore the differences between HTG-AP and other etiologies of pancreatitis, with an emphasis on systemic and local complications, recurrence, and long-term quality of life. Through its phased approach, CHPSG seeks to develop targeted strategies for the prevention and treatment of HTG-AP, ultimately improving patient outcomes.
